| Name | Valbenazine |
| Description | Valbenazine (NBI-98854), a highly selective vesicular monoamine transporter 2(VMAT2) inhibitor, is approved for the treatment of tardive dyskinesia. |
| Animal Research | The pooled long-term exposure (LTE) population included valbenazine-treated subjects from 3 studies: KINECT; KINECT 3; KINECT4. Safety assessments included adverse events (AEs), laboratory tests, vital signs, electrocardiograms (ECGs), and extrapyramidal symptom (EPS) scales. Psychiatric stability was monitored using the Positive and Negative Syndrome Scale (PANSS) and Calgary Depression Scale for Schizophrenia (CDSS) (SCHZ subgroup), as well as the Montgomery-?sberg Depression Rating Scale (MADRS) and Young Mania Rating Scale (YMRS) (mood subgroup). All data were analyzed descriptively[1]. |
| In vivo | Valbenazine appeared to be well tolerated in adults with TD who received up to 48 weeks of treatment. In addition to long-term efficacy results, Suggest that valbenazine may be appropriate for the long-term management of TD regardless of underlying psychiatric diagnosis (SCHZ disorder or mood disorder)[1]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (4.78 mM), Sonication is recommended.
DMSO : 50 mg/mL (119.45 mM), Sonication is recommended.
|
| Keywords | VMAT2 | vesicular | Valbenazine | transporter | NBI98854 | NBI 98854 | MonoamineTransporter | Monoamine Transporter | monoamine | Inhibitor | inhibit | Huntington | disease |
| Inhibitors Related | Diclofensine | Fostamatinib | Tetrabenazine | Tetrabenazine Racemate | Decynium 22 | Tetrabenazine Metabolite | Reserpine hydrochloride | (2R,3S,11bS)-Dihydrotetrabenazine | (+)-Tetrabenazine | Reserpine | FFN 511 | Nisoxetine |
| Related Compound Libraries | Bioactive Compound Library | Pediatric Drug Library | Membrane Protein-targeted Compound Library | Drug-induced Liver Injury (DILI) Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Drug Library |
United States
